2. Academic Validation
  3. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma

  • J Adv Pract Oncol. 2015 Jul-Aug;6(4):361-5. doi: 10.6004/jadpro.2015.6.4.6.
Lindsay Shelledy 1,  Danielle Roman 1
Affiliations

Affiliation

  • 1 West Penn Allegheny Oncology Network, Pittsburgh, Pennsylvania.
PMID: 26705496 DOI: 10.6004/jadpro.2015.6.4.6
Figures
Products